These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 22534667)

  • 1. Reduced expression of cyclin D2 is associated with poor recurrence-free survival independent of cyclin D1 in stage III non-small cell lung cancer.
    Ko E; Kim Y; Park SE; Cho EY; Han J; Shim YM; Park J; Kim DH
    Lung Cancer; 2012 Aug; 77(2):401-6. PubMed ID: 22534667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic effect of Bcl-2 and cyclin A2 on adverse recurrence-free survival in stage I non-small cell lung cancer.
    Ko E; Kim Y; Cho EY; Han J; Shim YM; Park J; Kim DH
    Ann Surg Oncol; 2013 Mar; 20(3):1005-12. PubMed ID: 23115005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance.
    Brambilla E; Moro D; Gazzeri S; Brambilla C
    J Pathol; 1999 Aug; 188(4):351-60. PubMed ID: 10440744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of phospho-pRb (Ser-807/811) level to exposure to tobacco smoke in primary non-small cell lung cancer.
    Ko E; Kim Y; Lee BB; Han J; Song SY; Shim YM; Park J; Kim DH
    Cancer Lett; 2009 Feb; 274(2):225-32. PubMed ID: 18938028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A risk-stratification model of non-small cell lung cancers using cyclin E, Ki-67, and ras p21: different roles of G1 cyclins in cell proliferation and prognosis.
    Dosaka-Akita H; Hommura F; Mishina T; Ogura S; Shimizu M; Katoh H; Kawakami Y
    Cancer Res; 2001 Mar; 61(6):2500-4. PubMed ID: 11289121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma.
    Burke L; Flieder DB; Guinee DG; Brambilla E; Freedman AN; Bennett WP; Jones RT; Borkowski A; Caporaso NA; Fleming M; Trastek V; Pairolero P; Tazelaar H; Midthun D; Jett JR; Liotta LA; Travis WD; Harris CC
    Clin Cancer Res; 2005 Jan; 11(1):232-41. PubMed ID: 15671551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
    Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
    Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of cyclin D1 and vascular endothelial growth factor(VEGF) in non-small cell lung carcinoma and their association with the prognosis].
    Liang RY; Liao ZS; Jiang SP; Zhang W; Li JG; Zheng DH
    Ai Zheng; 2003 Jan; 22(1):86-90. PubMed ID: 12561444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers.
    Nishio M; Koshikawa T; Yatabe Y; Kuroishi T; Suyama M; Nagatake M; Sugiura T; Ariyoshi Y; Mitsudomi T; Takahashi T
    Clin Cancer Res; 1997 Jul; 3(7):1051-8. PubMed ID: 9815783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The cyclin A, B1, D1 and E expression in advanced non-small cell lung cancer--stages IIIB-IV (preliminary report)].
    Kosacka M; Piesiak P; Porebska I; Korzeniewska A; Jankowska R
    Pol Merkur Lekarski; 2011 Apr; 30(178):253-8. PubMed ID: 21595169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients.
    Li R; An SJ; Chen ZH; Zhang GC; Zhu JQ; Nie Q; Xie Z; Guo AL; Mok TS; Wu YL
    Hum Pathol; 2008 Dec; 39(12):1792-801. PubMed ID: 18715616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer.
    Keum JS; Kong G; Yang SC; Shin DH; Park SS; Lee JH; Lee JD
    Br J Cancer; 1999 Sep; 81(1):127-32. PubMed ID: 10487623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence.
    Ito Y; Matsuura N; Sakon M; Miyoshi E; Noda K; Takeda T; Umeshita K; Nagano H; Nakamori S; Dono K; Tsujimoto M; Nakahara M; Nakao K; Taniguchi N; Monden M
    Hepatology; 1999 Jul; 30(1):90-9. PubMed ID: 10385644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression of AKT2, cyclin D1, and MMP-9 and their correlations to clinicopathologic features of non-small cell lung cancer].
    Wang J; Miao LJ; Wu YM; Wu YJ; Wang XC
    Ai Zheng; 2006 Jan; 25(1):69-72. PubMed ID: 16405753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression of cyclins D1 and E in predicting short-term survival in squamous cell carcinoma of the lung.
    Anton RC; Coffey DM; Gondo MM; Stephenson MA; Brown RW; Cagle PT
    Mod Pathol; 2000 Nov; 13(11):1167-72. PubMed ID: 11106072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of p27KIP1 expression in resected non-small cell lung cancers: analysis in combination with expressions of p16INK4A, pRB, and p53.
    Hirabayashi H; Ohta M; Tanaka H; Sakaguchi M; Fujii Y; Miyoshi S; Matsuda H
    J Surg Oncol; 2002 Dec; 81(4):177-84; discussion 184. PubMed ID: 12451621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinoma.
    Tsai MF; Wang CC; Chang GC; Chen CY; Chen HY; Cheng CL; Yang YP; Wu CY; Shih FY; Liu CC; Lin HP; Jou YS; Lin SC; Lin CW; Chen WJ; Chan WK; Chen JJ; Yang PC
    J Natl Cancer Inst; 2006 Jun; 98(12):825-38. PubMed ID: 16788156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
    Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
    Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer.
    Ko E; Lee BB; Kim Y; Lee EJ; Cho EY; Han J; Shim YM; Park J; Kim DH
    Clin Cancer Res; 2013 Mar; 19(5):1204-12. PubMed ID: 23319821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and molecular predictors of recurrence in stage I non-small cell lung cancer.
    Starnes SL; Pathrose P; Wang J; Succop P; Morris JC; Bridges J; Kupert EY; Anderson M
    Ann Thorac Surg; 2012 May; 93(5):1606-12. PubMed ID: 22440368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.